Table III.

Total cholesterol change with statin use for PWH and uninfected controls

	PWH (n = 843)	Uninfected controls (n = 464)	P value
Prestatin TC, mean (mg/dL)	203.3 (199.7, 206.9)	202.2 (197.5, 207.0)	.72
Poststatin TC, mean (mg/dL)	182.6 (179.0, 186.2)	173.7 (169.7, 177.6)	.002
Change in TC, mean (mg/dL)	−22.9 (−19.6, −26.2)	−28.5 (−23.7, −33.3)	.06
Difference in TC lowering, adjusted for age, sex, and race	5.4 (11.5, −0.7)	Referent	.08
Difference in TC lowering, adjusted for age, sex, race, and prestatin TC	4.0 (10.1, −2.1)	Referent	.20
Difference in TC lowering, adjusted for age, sex, race, prestatin TC, and whether or not statin intensity was ever reduced	3.8 (9.9, −2.3)	Referent	.22
Prestatin LDL-C, mean	127.7 (124.5, 131.0)	130.0 (125.7, 134.4)	.41
Poststatin LDL-C, mean	104.8 (102.0, 107.6)	103.0 (99.6, 106.5)	.44
Change in LDL-C, mean	−23.3 (−20.4, −26.3)	−27.0 (−22.6, −31.3)	.16
Difference in LDL-C lowering, adjusted for age, sex, and race	3.80 (9.11, −1.61)	Referent	.17
Difference in LDL-C lowering, adjusted for age, sex, race, and prestatin LDL-C	2.57 (7.12, −1.97)	Referent	.27
Participants on high-intensity statins (n = 256 for PWH, n = 129 for controls)
Change in TC, mean (mg/dL)	−22.1 (−28.7, −15.5)	−27.7 (−36.3, −19.2)	.32
Participants on moderate-intensity statins (n = 605 for PWH, n = 296 for controls)
Change in TC, mean (mg/dL)	−23.1 (−27.0, −19.2)	−26.5 (−32.0, −21.0)	.32
Participants on low-intensity statins (n = 73 for PWH, n = 197 for controls)
Change in TC, mean (mg/dL)	−17.7 (−24.6, −10.9)	−17.8 (−27.9, −7.7)	.99

Statin intensity was determined according to 2013 ACC/AHA guidelines, which classify “high”-intensity statins as those expected to achieve ≥50% LDL-c reduction, “moderate” a 30% to <50% LDL-c reduction, and “low” a <30% LDL-c reduction.⁶